

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM780770

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
JMB CAPITAL PARTNERS LENDING, LLC		01/13/2023	Limited Liability Company: CALIFORNIA
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	PHASEBIO PHARMACEUTICALS, INC.		
<b>Street Address:</b>	1 GREAT VALLEY PARKWAY, SUITE 30		
<b>City:</b>	MALVERN		
<b>State/Country:</b>	PENNSYLVANIA		
<b>Postal Code:</b>	19355		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>PROPERTY NUMBERS Total: 5</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	88107576	PHASEBIO	
<b>Serial Number:</b>	88847647	PB PHASEBIO	
<b>Serial Number:</b>	90808332	RETRIG	
<b>Serial Number:</b>	90808336	OPMIZTA	
<b>Serial Number:</b>	90808334	XYFT	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Email:</b>	jgu@cooley.com		
<b>Correspondent Name:</b>	JENNIFER GU C/O COOLEY LLP		
<b>Address Line 1:</b>	3175 HANOVER STREET		
<b>Address Line 4:</b>	PALO ALTO, CALIFORNIA 94304		
<b>ATTORNEY DOCKET NUMBER:</b>	309646-206		
<b>NAME OF SUBMITTER:</b>	Jennifer Gu		
<b>SIGNATURE:</b>	/Jennifer Gu/		
<b>DATE SIGNED:</b>	01/13/2023		
<b>Total Attachments: 6</b>			

CH \$140.00 88107576

source=JMB\_PhaseBio -Termination and Release of Security Interest In Intellectual Property [Execution Version]#page1.tif

source=JMB\_PhaseBio -Termination and Release of Security Interest In Intellectual Property [Execution Version]#page2.tif

source=JMB\_PhaseBio -Termination and Release of Security Interest In Intellectual Property [Execution Version]#page3.tif

source=JMB\_PhaseBio -Termination and Release of Security Interest In Intellectual Property [Execution Version]#page4.tif

source=JMB\_PhaseBio -Termination and Release of Security Interest In Intellectual Property [Execution Version]#page5.tif

source=JMB\_PhaseBio -Termination and Release of Security Interest In Intellectual Property [Execution Version]#page6.tif

**TERMINATION AND RELEASE OF SECURITY INTEREST  
IN INTELLECTUAL PROPERTY**

This **TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY**, dated as of January 13, 2023 (“Release”), is made by JMB CAPITAL PARTNERS LENDING, LLC a California limited liability company, in its capacity as administrative agent and collateral agent (the “Agent”) for itself and for various other financial institutions from time to time a party to the Loan Agreement (collectively, the “Lenders”) in favor of PHASEBIO PHARMACEUTICALS, INC., a Delaware corporation (the “Grantor”).

**WHEREAS**, pursuant to those certain Assignments of Intellectual Property Security Agreement dated as of October 3, 2022 (“IPSA Assignments”), Agent acquired the security interests in the Intellectual Property Collateral, notice of which were recorded with the United States Patent and Trademark Office (“USPTO”) at Reel 7312, Frame 0487 and Reel 056405, Frame 0575, respectively;

**WHEREAS**, Agent recorded at the USPTO those IPSA Assignments at Reel 7860, Frame 0251 and Reel 061606, Frame 0035;

**WHEREAS**, Grantor executed and delivered to the Agent that certain Intellectual Property Security Agreement dated as of October 7, 2022 (“IP Security Agreement of Oct. 7, 2022”), notice of which was recorded at the USPTO at Reel 7863, Frame 0510 and Reel 061367, Frame 0674, respectively;

**WHEREAS**, Grantor executed and delivered to the Agent that certain Intellectual Property Security Agreement dated as of October 28, 2022 (“IP Security Agreement of Oct. 28, 2022”), notice of which was recorded at the USPTO at Reel 7880, Frame 0866 and Reel 061601, Frame 0001, respectively; and

**WHEREAS**, the Grantor has requested that the Agent enter into this Release in order to effectuate, evidence and record the release to the Grantor of any and all right, title and interest the Agent and Lenders may have in the Intellectual Property Collateral.

**NOW THEREFORE**, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Agent and Grantor agree as follows:

**SECTION 1. Release of Security Interest.** Agent, on behalf of itself and the Lenders, their successors, legal representatives and assigns, hereby terminates, releases and discharges any and all security interests that it has in the Intellectual Property Collateral pursuant to the IPSA Assignments, the IP Security Agreement of Oct. 7, 2022, and/or the IP Security Agreement as of Oct. 28, 2022.

**SECTION 2. Further Assurances.** Agent agrees, at the Grantor’s expense, to take all further actions, and provide to the Grantor and its successors, assigns and legal representatives all such cooperation and assistance, including, without limitation, the execution and delivery of any

and all further documents or other instruments, as the Grantor and its successors, assigns and legal representatives may reasonably request in order to confirm, effectuate or record this Release.

**SECTION 3. Choice of Law.** This Release shall be governed by and construed in accordance with the laws of the State of New York.

**IN WITNESS WHEREOF**, the Agent has caused this Termination and Release of Security Interest in Intellectual Property to be duly executed as of the date first set forth above.

Agent:

**JMB CAPITAL PARTNERS LENDING,  
LLC**

By: DocuSigned by: VIKAS TANDON  
00042F0F989444B  
Name: Vikas Tandon  
Title: Chief Investment Officer

EXHIBIT A

Copyrights

Description

Registration/  
Application  
Number

Registration/  
Application  
Date

None

EXHIBIT B

Patents

Title	Appln. No.	Appln. Date	Registration No.	Registration Date
MODIFIED VASOACTIVE INTESTINAL PEPTIDES	12/857,103	8/16/2010	9,029,505	5/12/2015
MODIFIED VASOACTIVE INTESTINAL PEPTIDES	14/681,597	4/8/2015	9,700,598	7/11/2017
MODIFIED VASOACTIVE INTESTINAL PEPTIDES	15/621,320	6/13/2017		
A METHOD FOR ADMINISTERING A SUSTAINED RELEASE FORMULATION	9919032	03/20/2018		
MULTIMERIC ELP FUSION CONSTRUCTS	11/620,034	1/4/2007	7,709,227	5/4/2010
ELP FUSION PROTEINS COMPRISING PARATHYROID HORMONE FOR CONTROLLED AND SUSTAINED RELEASE	17/633,369	8/7/2020		
USE OF MODIFIED VASOACTIVE INTESTINAL PEPTIDES IN THE TREATMENT OF HYPERTENSION	14/124,612	6/6/2012	9,561,262	2/7/2017
USE OF MODIFIED VASOACTIVE INTESTINAL PEPTIDES IN THE TREATMENT OF HYPERTENSION	15/276,151	9/26/2016	10,940,182	3/9/2021
FORMULATIONS OF ACTIVE AGENTS FOR SUSTAINED RELEASE	14/099,590	12/6/2013		
FORMULATIONS OF ACTIVE AGENTS FOR SUSTAINED RELEASE	15/355,386	11/18/2016	9,919,032	3/20/2018
METHODS AND COMPOSITIONS FOR TREATING CYSTIC FIBROSIS	15/308,626	5/8/2015	11,052,132	7/6/2021
ELP FUSION PROTEINS FOR CONTROLLED AND SUSTAINED RELEASE	15/527,985	11/20/2015	10,72,590	7/28/2020
METHODS AND COMPOSITIONS FOR TREATING MUSCLE DISEASE AND DISORDERS	15/546,037	2/9/2016	10,688,156	6/23/2020
ELP FUSION PROTEINS FOR CONTROLLED AND SUSTAINED RELEASE	16/099,261	11/6/2018		
ELP FUSION PROTEINS COMPRISING PARATHYROID HORMONE FOR CONTROLLED AND SUSTAINED RELEASE	62/884,792	8/9/2019		
METALLOENZYME INHIBITOR COMPOUNDS	15/858,015	12/29/2017	10,538,511	1/21/2020
METALLOENZYME INHIBITOR COMPOUNDS	15/857,950	12/29/2017	10,085,984	10/2/2018
METALLOENZYME INHIBITOR COMPOUNDS	16/124,846	9/7/2018	11,040,034	6/22/2021
METALLOENZYME INHIBITOR COMPOUNDS	17/421,567	1/8/2020		
PHARMACOKINETIC & PHARMACODYNAMIC MODEL FOR DETERMINING EFFECTIVE DOSE OF ANTI-TICAGRELOR ANTIBODY	17/739,491	5/9/2022		
METALLOENZYME INHIBITOR COMPOUNDS	17/350,726	6/17/2021		

<b>Title</b>	<b>Appln. No.</b>	<b>Appln. Date</b>	<b>Registration No.</b>	<b>Registration Date</b>
METHODS AND COMPOSITIONS FOR TREATING CYSTIC FIBROSIS	17/365,443	7/1/2021		
METALLOENZYME INHIBITOR COMPOUNDS	17/462,909	8/31/2021		
METHODS AND COMPOSITIONS FOR TREATING MUSCLE DISEASE AND DISORDERS	17/583,883	1/25/2022		
METALLOENZYME INHIBITOR COMPOUNDS	16/746,098	1/17/20	11,136,309	10/5/2021
THERAPEUTIC AGENTS COMPRISING A BMP-9 PEPTIDE AND ELEASTIN-LIKE PEPTIDE	16/720,970	12/19/2019	11,103,558	8/31/2021
METHODS AND COMPOSITIONS FOR TREATING MUSCLE DISEASE AND DISORDERS	16/907,759	6/22/20	11,266,719	3/8/2022
ELP FUSION PROTEINS FOR CONTROLLED AND SUSTAINED RELEASE	16/939,624	7/27/20		
METHODS OF REVERSING TICAGRELOR ACTIVITY	17/278,075	09/202/20192		
VASOACTIVE INTESTINAL PEPTIDE FUSION PROTEINS FOR THE TREATMENT OF COVID-19	63/032,244	5/29/20		
METHODS OF TREATMENT OF HYPERTENSION WITH VIP-ELP FUSION POLYPEPTIDES	63/131,491	12/29/20		
PHARMACOKINETIC & PHARMACODYNAMIC MODEL FOR DETERMINING EFFECTIVE DOSE OF ANTI-TICAGRELOR ANTIBODY	63/186,515	5/10/21		

EXHIBIT C

Trademarks

<u>Description</u>	<u>Application Number</u>	<u>Application Date</u>
PHASEBIO	88107576	09/06/2018
PB PHASEBIO	88847647	03/25/2020
RETRIG	90808332	07/02/2021
OPMIZTA	90808336	07/02/2021
XYFT	90808334	07/02/2021